BioNTech SE

As of September 30, 2026, BioNTech SE carries a market capitalization of 24.37B, placing it among publicly traded companies globally. Its enterprise value stands at 8.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioNTech SE's next confirmed earnings release is scheduled for March 2, 2027.

As of September 30, 2026, BioNTech SE has 247.93M shares outstanding.

These figures are as of September 30, 2026. The price-to-sales ratio is 8.96, and the price-to-book ratio stands at 1.21.

These figures are as of September 30, 2026. The EV/Sales ratio of 2.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 8.17B versus a market cap of 24.37B, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2026, BioNTech SE maintains a current ratio of 8.55, meaning it holds 8.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.03, indicating elevated leverage, while an interest coverage ratio of -65.32 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2026, BioNTech SE posted a negative return on equity (ROE) of -8.14, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.10, reflecting losses generated across the asset base. The company generates approximately 351,373.29 in revenue per employee across its workforce of 7,807.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.16 indicates how many times BioNTech SE sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2026, BioNTech SE recorded 46.47M in income tax expense. The company reported a pretax loss of -1.62B and -1.67B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on November 6, 2026, BioNTech SE's stock has declined approximately 15.33% over the past 52 weeks. The 50-day moving average sits at 94.66, while the 200-day moving average is 96.51.

Over the twelve months ended September 30, 2026, BioNTech SE generated 2.74B in revenue and converted that into -1.67B in net income, yielding earnings per share of -6.66. EBITDA reached -1.35B, while operating income came in at -1.99B.

As of September 30, 2026, BioNTech SE holds 16.61B in cash and equivalents against 407.80M in total debt, resulting in a net debt position of -11.37B. Total book value stands at 20.07B, with working capital of 15.69B providing operational flexibility.

BioNTech SE produced -261.59M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -277.57M in capital expenditures, free cash flow totaled -539.16M - equivalent to -2.16 per share.

Over the twelve months ended September 30, 2026, BioNTech SE posted a gross margin of 75.00, reflecting its pricing power and cost economics. The operating margin of -72.66 and net profit margin of -60.87 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -2.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.53, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioNTech SE shareholders.

As of September 30, 2026, BioNTech SE has an Altman Z-Score of 7.22, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.